Core Viewpoint - Plymouth Industrial REIT, Inc. has received stockholder approval for an all-cash acquisition by Makarora Management LP and Ares Alternative Credit funds, valued at approximately $2.1 billion [1][3]. Group 1: Acquisition Details - The acquisition involves Makarora and Ares agreeing to purchase all outstanding shares of Plymouth's common stock and limited partnership interests for $22.00 per share [3]. - The transaction is expected to be completed around January 27, 2026, pending customary closing conditions [4]. Group 2: Company Overview - Plymouth Industrial REIT, Inc. is a vertically integrated real estate investment company focused on acquiring, owning, and managing industrial properties [5].

Core Viewpoint - LakeShore Biopharma has received a preliminary non-binding proposal from Oceanpine Capital to acquire all outstanding ordinary shares at a price of US$0.86 per share, representing a premium over recent trading prices [1][2][10]. Group 1: Proposal Details - The proposed purchase price of US$0.86 per Ordinary Share represents a premium of 10.3% to the last closing price on August 15, 2025, and an 11.4% premium to the average closing price over the last 15 trading days [2][10]. - Oceanpine Capital plans to fund the transaction using rollover equity and available cash, ensuring that the proposal is not subject to a financing condition [2][11]. - Oceanpine Capital has engaged White & Case LLP as its international legal advisor for the proposed transaction [2][12]. Group 2: Company Background - LakeShore Biopharma is a global biopharmaceutical company focused on developing vaccines and therapeutic biologics for infectious diseases and cancer, utilizing its proprietary PIKA® immunomodulating technology platform [5]. - The company operates in China, Singapore, and the Philippines, led by a management team with extensive local and global experience in the biopharmaceutical industry [5]. Group 3: Board's Response - The Board of LakeShore Biopharma has just received the proposal and will review it to determine the best course of action for the company and its shareholders [3][4].